CANSINOBIO Trademark

Trademark Overview


On Wednesday, September 20, 2023, a trademark application was filed for CANSINOBIO with the United States Patent and Trademark Office. The USPTO has given the CANSINOBIO trademark a serial number of 98189642. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, July 23, 2024. This trademark is owned by CANSINO BIOLOGICS INC.. The CANSINOBIO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, antivirals; Chemical preparations for pharmaceutical purposes, namely, for the treatment of infectious diseases; Vaccines; Medicines for the treatment of infectious diseases; Cultures of microorganisms for medical or veterinary use; Chemical preparations for medical purposes, namely, for the treatment of infectious diseases; Injectable pharmaceuticals for treatment of anaphylactic reactions; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; biochemical medicines for the treatment of infectious diseases, namely, biochemical reagents for medical purposes; Bacteriological culture mediums
cansinobio

General Information


Serial Number98189642
Word MarkCANSINOBIO
Filing DateWednesday, September 20, 2023
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, July 23, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing5 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, July 23, 2024

Trademark Statements


Description of MarkThe mark consists of stylized letters "CANSINOBIO".
Goods and ServicesPharmaceutical preparations, namely, antivirals; Chemical preparations for pharmaceutical purposes, namely, for the treatment of infectious diseases; Vaccines; Medicines for the treatment of infectious diseases; Cultures of microorganisms for medical or veterinary use; Chemical preparations for medical purposes, namely, for the treatment of infectious diseases; Injectable pharmaceuticals for treatment of anaphylactic reactions; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; biochemical medicines for the treatment of infectious diseases, namely, biochemical reagents for medical purposes; Bacteriological culture mediums
Indication of Colors claimedColor is not claimed as a feature of the mark.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, October 7, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCANSINO BIOLOGICS INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressTianjin 300000
CN

Party NameCANSINO BIOLOGICS INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressTianjin 300000
CN

Trademark Events


Event DateEvent Description
Saturday, September 23, 2023NEW APPLICATION ENTERED
Saturday, October 7, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, May 20, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, May 14, 2024ASSIGNED TO EXAMINER
Monday, May 20, 2024NON-FINAL ACTION E-MAILED
Thursday, June 13, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, June 13, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, June 13, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, June 18, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 3, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 23, 2024PUBLISHED FOR OPPOSITION
Tuesday, July 23, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Monday, May 20, 2024NON-FINAL ACTION WRITTEN